Privium Fund Management B.V. purchased a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) in the 3rd quarter, HoldingsChannel reports. The fund purchased 33,680 shares of the company’s stock, valued at approximately $429,000. Other hedge funds also recently added to or reduced their stakes in the company. International Assets Investment Management LLC […]
Privium Fund Management B.V. acquired a new position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 33,680 shares of the company’s stock, valued at approximately $429,000. Privium Fund Management B.V. owned 0.08% of 4D […]
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have received an average rating of “Moderate Buy” from the eight brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 […]
HC Wainwright restated their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a research report report published on Monday morning, Benzinga reports. HC Wainwright currently has a $36.00 target price on the stock. Other research analysts also recently issued reports about the company. Chardan Capital boosted their price objective on […]
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) – Chardan Capital lifted their FY2023 EPS estimates for 4D Molecular Therapeutics in a research report issued on Tuesday, July 11th. Chardan Capital analyst G. Livshits now anticipates that the company will earn ($2.66) per share for the year, up from their previous estimate of ($3.13). The […]